Dr. Hiram A Gay, M.D.
Claim this profileWashington University School of Medicine
Studies Prostate Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
31 drugs studied
Area of expertise
1Prostate Cancer
Stage I
Stage II
White blood cell count (WBC)
2Squamous Cell Carcinoma
Stage III
p16 positive
p16 negative
Affiliated Hospitals
Clinical Trials Hiram A Gay, M.D. is currently running
Circulating Tumor DNA
for Cancer
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Recruiting1 award N/A1 criteria
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
More about Hiram A Gay, M.D.
Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Hiram A Gay, M.D. has experience with
- Radium-223 Dichloride
- Cabozantinib
- Avelumab
- Stereotactic Body Radiation Therapy
- HDR Brachytherapy
- Salvage Radiotherapy
Breakdown of trials Hiram A Gay, M.D. has run
Prostate Cancer
Squamous Cell Carcinoma
Neck Cancer
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hiram A Gay, M.D. specialize in?
Hiram A Gay, M.D. focuses on Prostate Cancer and Squamous Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Hiram A Gay, M.D. currently recruiting for clinical trials?
Yes, Hiram A Gay, M.D. is currently recruiting for 8 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Hiram A Gay, M.D. has studied deeply?
Yes, Hiram A Gay, M.D. has studied treatments such as Radium-223 Dichloride, Cabozantinib, Avelumab.
What is the best way to schedule an appointment with Hiram A Gay, M.D.?
Apply for one of the trials that Hiram A Gay, M.D. is conducting.
What is the office address of Hiram A Gay, M.D.?
The office of Hiram A Gay, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.